FIG. 5.
Expression of RARs, PPARβ/δ, FABP5, and PPARβ/δ target genes in lean, obese, RA- and GW0742-treated mice. (a and b) Levels of mRNA for denoted RARs (a) and PPARβ/δ and FABP5 (b) in the adipose tissues of lean, obese, and RA-treated obese mice (n = 3 per group; *, P < 0.005; **, P = 0.04 [versus lean mice]). (c) The top panel shows immunoblots of FABP5 in the adipose tissues of lean, obese, and RA-treated mice. Each lane represents an individual mouse. The bottom panel shows the quantitation of the immunoblots in the top panels (‡, P = 0.07 [versus untreated obese mice]). (d) Levels of mRNA for the denoted genes in WAT and skeletal muscles of lean, obese, and obese mice treated with RA for 5 weeks (n = 3; #, P = 0.05 [versus untreated obese mice]). (e) The top panel shows immunoblots of total and phospho-Akt1 in WAT of lean, obese, and mice treated with RA for 5 weeks. The bottom panel shows the quantitation of the immunoblots in the top panels (*, P < 0.005 [versus obese mice]). (f) Levels of mRNA for the denoted PPARβ/δ target genes in adipose tissues and skeletal muscles of untreated mice and mice treated with RA for 2 days. #, P = 0.05 (versus untreated obese mice).